Spero Therapeutics (NASDAQ:SPRO – Get Rating) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a research note issued on Tuesday, Zacks.com reports. According to Zacks, “Spero Therapeutics Inc. is a multi-asset, clinical-stage biopharmaceutical company. It focused on identifying, developing and commercializing novel treatments for multi-drug resistant bacterial infections. […]

Related Keywords

United States , Cambridge , Cambridgeshire , United Kingdom , , Allspring Global Investments Holdings , Securities Exchange Commission , Zacks Investment Research , Marshall Wace , Patriot Financial Group Insurance Agency , Aquilo Capital Management Llc , Spero Therapeutics Inc , Barclays Plc , Spero Therapeutics , Get Rating , Aquilo Capital Management , Exchange Commission , Financial Group Insurance Agency , Global Investments Holdings , Nasdaq Spro , Aspro , Medical , Downgrade ,